Gefitinib (Iressa) is the first oral EGFR tyrosine kinase inhibitor and it brings benefits to non-
small cell lung cancer patients with EGFR mutation. In this study, a simple, rapid and …

Lung cancer is the most frequently diagnosed cancer worldwide and the one that causes the
highest mortality. In order to understand the disease and to develop new treatments, in vitro …

Gefitinib, the first approved oral epidermal growth factor receptor (EGFR) inhibitor, has been
demonstrated effective in cancers with EGFR active mutations. In this study, we established …

Background Numerous reports have shown that a combination of two or more drugs leads to
better cancer treatment. Inhibitors of zeste homology 2 and epidermal growth factor receptor …

Cancer patients generally has a high risk of thrombotic diseases. However, anticoagulant
therapy always aggravates bleeding risks. Rivaroxaban is one of the most widely used direct …

The aim of this study is to examine the effect of cordyceps acid (CA) on lung cancer in mice.
A lung cancer animal model was established by inoculating lung cancer cells under the …

Objective This study aimed to examine the association of clinical prognostic factors with
epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced …

In the present work, we apply a geometric network approach to study common biological
features of anticancer drug response. We use for this purpose the panel of 60 human cell …

Current methods of cancer therapy have demonstrated enormous potential in tumor
inhibition. However, a high dosage regimen of chemotherapy results in various …

This study investigates the molecular mechanism of FTO m6A demethylase in non-small cell
lung cancer (NSCLC) and gefitinib resistance using GEO and TCGA databases …